{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:05:30Z","timestamp":1791007530146,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.diabet.2013.03.001","type":"journal-article","created":{"date-parts":[[2013,5,2]],"date-time":"2013-05-02T16:17:58Z","timestamp":1367511478000},"page":"195-201","source":"Crossref","is-referenced-by-count":60,"title":["Incretin dysfunction in type 2 diabetes: Clinical impact and future perspectives"],"prefix":"10.1016","volume":"39","author":[{"given":"B.","family":"Ahr\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2013.03.001_bib0005","first-page":"620","article-title":"Sur les possibilit\u00e9s d\u2019un traitement du diab\u00e8te par l\u2019incr\u00e9tine","volume":"12","author":"LaBarre","year":"1932","journal-title":"Bull Acad R Med Belg"},{"key":"10.1016\/j.diabet.2013.03.001_bib0010","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF02023116","article-title":"\u00dcber das insulinotrope Hormon der Darmschleimhaut (Duodenin)","volume":"177","author":"Heller","year":"1935","journal-title":"Arch Exp Pharmakol"},{"key":"10.1016\/j.diabet.2013.03.001_bib0015","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJM199205143262003","article-title":"Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus","volume":"326","author":"Gutniak","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2013.03.001_bib0020","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.yexcr.2011.01.010","article-title":"GLP-1 for type 2 diabetes","volume":"317","author":"Ahr\u00e9n","year":"2011","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.diabet.2013.03.001_bib0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0140-6736(64)90011-X","article-title":"New interpretation of oral glucose tolerance","volume":"2","author":"McIntyre","year":"1964","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2013.03.001_bib0030","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1210\/jcem-24-10-1076","article-title":"Plasma insulin responses to oral and intravenous glucose administration","volume":"24","author":"Elrick","year":"1964","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2013.03.001_bib0035","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2013.03.001_bib0040","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1677\/JOE-07-0460","article-title":"The augmenting effect on insulin secretion by oral versus intravenous glucose is exaggerated by high-fat diet in mice","volume":"197","author":"Ahr\u00e9n","year":"2008","journal-title":"J Endocrinol"},{"key":"10.1016\/j.diabet.2013.03.001_bib0045","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1210\/jc.2010-2435","article-title":"Impaired regulation of the incretin effect in patients with type 2 diabetes","volume":"96","author":"Bagger","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2013.03.001_bib0050","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.2337\/db07-0100","article-title":"Reduced incretin effect in type 2 diabetes. Cause or consequence of the diabetic state?","volume":"56","author":"Knop","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2013.03.001_bib0055","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1210\/jc.2010-2178","article-title":"Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as isoglycemic intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes","volume":"96","author":"Vardarli","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2013.03.001_bib0060","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1210\/jc.2011-0299","article-title":"The dynamic incretin adaptation and type 2 diabetes","volume":"96","author":"Ahr\u00e9n","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2013.03.001_bib0065","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.regpep.2004.06.020","article-title":"Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes","volume":"122","author":"Nauck","year":"2004","journal-title":"Regul Pept"},{"key":"10.1016\/j.diabet.2013.03.001_bib0070","doi-asserted-by":"crossref","first-page":"E1144","DOI":"10.1152\/ajpendo.00571.2005","article-title":"Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance","volume":"291","author":"Muscelli","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.diabet.2013.03.001_bib0075","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1900\/RDS.2011.8.293","article-title":"Physiology of incretins in health and disease","volume":"8","author":"Deacon","year":"2011","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.diabet.2013.03.001_bib0080","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1210\/jc.2009-0366","article-title":"Differential islet and incretin hormone responses in morning versus afternoon after standardized meal in healthy men","volume":"94","author":"Lindgren","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2013.03.001_bib0085","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/B978-0-12-381517-0.00007-2","article-title":"Incretin hormone secretion over the day","volume":"84","author":"Ahren","year":"2010","journal-title":"Vitam Horm"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.diabet.2013.03.001_bib0090","doi-asserted-by":"crossref","first-page":"S251","DOI":"10.2337\/dc11-s227","article-title":"Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes","volume":"34","author":"Holst","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2013.03.001_bib0095","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2337\/db09-1899","article-title":"Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired \u03b2-cell function","volume":"59","author":"Meier","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2013.03.001_bib0100","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2337\/diabetes.50.3.609","article-title":"Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients","volume":"50","author":"Vilsb\u00f8ll","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2013.03.001_bib0105","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jc.86.8.3717","article-title":"Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients","volume":"86","author":"Toft-Nielsen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2013.03.001_bib0110","doi-asserted-by":"crossref","first-page":"678","DOI":"10.2337\/db07-1124","article-title":"Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance","volume":"57","author":"Vollmer","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2013.03.001_bib0115","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00125-010-1896-4","article-title":"Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?","volume":"54","author":"Nauck","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2013.03.001_bib0120","first-page":"E779","article-title":"Incretin and islet hormonal responses to fat and protein ingestion in healthy men","volume":"295","author":"Carr","year":"2008","journal-title":"Am J Physiol"},{"key":"10.1016\/j.diabet.2013.03.001_bib0125","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1210\/jc.2009-2054","article-title":"Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, non-diabetic, men","volume":"95","author":"Carr","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2013.03.001_bib0130","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/j.1463-1326.2011.01420.x","article-title":"Dissociated incretin hormone response to protein versus fat ingestion in obese subjects","volume":"13","author":"Lindgren","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2013.03.001_bib0135","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.regpep.2012.06.004","article-title":"Synergism by individual macronutrients explains the marked early GLP-1 and islet hormone responses to mixed meal challenge in mice","volume":"178","author":"Ahlkvist","year":"2012","journal-title":"Regul Pept"},{"key":"10.1016\/j.diabet.2013.03.001_bib0140","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2337\/db08-1589","article-title":"Association of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretion","volume":"58","author":"Mussig","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2013.03.001_bib0145","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.2337\/diacare.24.9.1640","article-title":"Impaired incretin responses after mixed meal is associated with insulin resistance in nondiabetic men","volume":"24","author":"Rask","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2013.03.001_bib0150","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1530\/eje.0.1370127","article-title":"Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance","volume":"137","author":"Ahr\u00e9n","year":"1997","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.diabet.2013.03.001_bib0155","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.metabol.2003.11.011","article-title":"Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance","volume":"53","author":"Rask","year":"2004","journal-title":"Metabolism"},{"key":"10.1016\/j.diabet.2013.03.001_bib0160","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/BF01296800","article-title":"Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycaemia after total gastrectomy","volume":"36","author":"Miholic","year":"1991","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.diabet.2013.03.001_bib0165","first-page":"93","article-title":"Glucagon-like peptide-1 (GLP-1) dynamics following bariatric surgery: a signpost to a new frontier","volume":"9","author":"Neff","year":"2013","journal-title":"Curr Diabet Rev"},{"key":"10.1016\/j.diabet.2013.03.001_bib0170","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/clpt.2010.184","article-title":"Dipeptidyl peptidase-4 inhibition administered in combination with metformin result in an additive increase in the plasma concentrations of active GLP-1","volume":"88","author":"Migoya","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.diabet.2013.03.001_bib0285","article-title":"Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells","author":"Kappe","year":"2012","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.diabet.2013.03.001_bib0180","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/0026-0495(87)90153-3","article-title":"Effect of porcine gastric inhibitory polypeptide on \u03b2-cell function in type I and type II diabetes mellitus","volume":"36","author":"Krarup","year":"1987","journal-title":"Metabolism"},{"key":"10.1016\/j.diabet.2013.03.001_bib0185","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide I [(7-36) amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabet.2013.03.001_bib0190","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0026-0495(03)00327-5","article-title":"Similar insulin secretory response to a gastric inhibitory polypeptide bolus injections at euglycaemia in first-degree relatives of patients with type 2 diabetes and control subjects","volume":"52","author":"Meier","year":"2003","journal-title":"Metabolism"},{"key":"10.1016\/j.diabet.2013.03.001_bib0195","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1007\/s00125-005-1863-7","article-title":"Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes","volume":"48","author":"Meier","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2013.03.001_bib0200","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.regpep.2007.07.002","article-title":"The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance","volume":"144","author":"Knop","year":"2007","journal-title":"Regul Pept"},{"key":"10.1016\/j.diabet.2013.03.001_bib0205","doi-asserted-by":"crossref","first-page":"13634","DOI":"10.1210\/jc.2011-2594","article-title":"Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects","volume":"97","author":"Hansen","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2013.03.001_bib0210","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00125-008-1195-5","article-title":"Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes","volume":"52","author":"H\u00f8jberg","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2013.03.001_bib0215","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2337\/diabetes.52.2.380","article-title":"Influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects","volume":"52","author":"Kjems","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2013.03.001_bib0220","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s001250051461","article-title":"Characterization of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion","volume":"43","author":"Fritsche","year":"2000","journal-title":"Diabetologia"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.diabet.2013.03.001_bib0225","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.2337\/diabetes.51.2007.S122","article-title":"Clinical characterization of insulin secretion as the basis for genetic analyses","volume":"51","author":"Stumvoll","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2013.03.001_bib0230","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0014-2999(98)00236-2","article-title":"Potentiated beta-cell response to non-glucose stimuli in insulin-resistance C57BL\/6J mice","volume":"350","author":"Simonsson","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.diabet.2013.03.001_bib0235","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00125-012-2776-x","article-title":"Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signaling in the beta cell in mouse models of diabetes","volume":"56","author":"Kang","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2013.03.001_bib0240","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1007\/s00125-010-1876-8","article-title":"Genetic variants affecting incretin sensitivity and incretin secretion","volume":"53","author":"Mussig","year":"2010","journal-title":"Diabetologia"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.diabet.2013.03.001_bib0245","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1463-1326.2012.01648.x","article-title":"Impairment of GLP-1-induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia","volume":"14","author":"Herzberg-Sch\u00e4fer","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2013.03.001_bib0250","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1007\/s00125-009-1532-3","article-title":"Genetic influences on the insulin response of the beta cell to different secretagogues","volume":"52","author":"Simonis-Bik","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2013.03.001_bib0255","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11892-007-0056-9","article-title":"GLP-1 based therapy for type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors","volume":"7","author":"Ahr\u00e9n","year":"2007","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.diabet.2013.03.001_bib0260","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/edn.221","article-title":"Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors","volume":"10","author":"Ahr\u00e9n","year":"2013","journal-title":"Eur Diabetes Nursing"},{"key":"10.1016\/j.diabet.2013.03.001_bib0265","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2174\/1566524053766004","article-title":"Type 2 diabetes, insulin secretion and \u03b2-cell mass","volume":"5","author":"Ahr\u00e9n","year":"2005","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.diabet.2013.03.001_bib0270","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI60016","article-title":"Glucagoncentric restructuring of diabetes: a pathophysiologic and therapeutic makeover","volume":"122","author":"Unger","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabet.2013.03.001_bib0275","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/diabetes.44.11.1249","article-title":"Overview of 6 year's therapy of type II diabetes: a progressive disease","volume":"44","author":"UK Prospective Diabetes Study Group. UKPDS 16","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2013.03.001_bib0280","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/S0140-6736(12)60479-6","article-title":"Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomized, controlled trial","volume":"379","author":"Gallwitz","year":"2012","journal-title":"Lancet"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363613000438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363613000438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T08:22:57Z","timestamp":1539678177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363613000438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S1262363613000438"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2013.03.001","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}